Background: The single-agent activity of the vinca alkaloid vinorelbine (Navel-bine®) in patients with relapsed or refractory nonseminomatous germ cell tumors was evaluated. Patients and Methods: Seven heavily pretreated patients received weekly an infusion (30 min) of vinorelbine at a dose of 30 mg/m2. Results: No responses (complete and partial remissions or no change) were achieved. We observed myelotoxicity with grade 3 leukopenia in 4 patients and grade 3 throm-bocytopenia in 2. No neurotoxicity was noted. Two patients had skin reactions at the site of infusion. Conclusions: Due to slow recruitment of patients, this phase II study has been terminated early. No role for vinorelbine was found in this patient group with an extremely unfavorable prognosis. The use of vinorelbine in combination regimens remains an issue of investigation.

Keywords:
Phase II study, Testicular cancer, Vinorelbine
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.